Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Regulation of energy homeostasis by bombesin receptor subtype-3: selective receptor agonists for the treatment of obesity.

Guan XM, Chen H, Dobbelaar PH, Dong Y, Fong TM, Gagen K, Gorski J, He S, Howard AD, Jian T, Jiang M, Kan Y, Kelly TM, Kosinski J, Lin LS, Liu J, Marsh DJ, Metzger JM, Miller R, Nargund RP, Palyha O, Shearman L, Shen Z, Stearns R, Strack AM, Stribling S, Tang YS, Wang SP, White A, Yu H, Reitman ML.

Cell Metab. 2010 Feb 3;11(2):101-12. doi: 10.1016/j.cmet.2009.12.008. Epub 2010 Jan 21.

2.

Body temperature as a mouse pharmacodynamic response to bombesin receptor subtype-3 agonists and other potential obesity treatments.

Metzger JM, Gagen K, Raustad KA, Yang L, White A, Wang SP, Craw S, Liu P, Lanza T, Lin LS, Nargund RP, Guan XM, Strack AM, Reitman ML.

Am J Physiol Endocrinol Metab. 2010 Nov;299(5):E816-24. doi: 10.1152/ajpendo.00404.2010. Epub 2010 Aug 31.

3.

Antiobesity effect of MK-5046, a novel bombesin receptor subtype-3 agonist.

Guan XM, Metzger JM, Yang L, Raustad KA, Wang SP, Spann SK, Kosinski JA, Yu H, Shearman LP, Faidley TD, Palyha O, Kan Y, Kelly TM, Sebhat I, Lin LS, Dragovic J, Lyons KA, Craw S, Nargund RP, Marsh DJ, Strack AM, Reitman ML.

J Pharmacol Exp Ther. 2011 Feb;336(2):356-64. doi: 10.1124/jpet.110.174763. Epub 2010 Oct 29.

4.

Biology and pharmacology of bombesin receptor subtype-3.

Majumdar ID, Weber HC.

Curr Opin Endocrinol Diabetes Obes. 2012 Feb;19(1):3-7. doi: 10.1097/MED.0b013e32834ec77d. Review.

PMID:
22157398
5.

Synthesis and SAR of derivatives based on 2-biarylethylimidazole as bombesin receptor subtype-3 (BRS-3) agonists for the treatment of obesity.

Liu J, He S, Jian T, Dobbelaar PH, Sebhat IK, Lin LS, Goodman A, Guo C, Guzzo PR, Hadden M, Henderson AJ, Pattamana K, Ruenz M, Sargent BJ, Swenson B, Yet L, Tamvakopoulos C, Peng Q, Pan J, Kan Y, Palyha O, Kelly TM, Guan XM, Howard AD, Marsh DJ, Metzger JM, Reitman ML, Wyvratt MJ, Nargund RP.

Bioorg Med Chem Lett. 2010 Apr 1;20(7):2074-7. doi: 10.1016/j.bmcl.2010.02.076. Epub 2010 Feb 21.

PMID:
20219372
6.

Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents.

Fong TM, Guan XM, Marsh DJ, Shen CP, Stribling DS, Rosko KM, Lao J, Yu H, Feng Y, Xiao JC, Van der Ploeg LH, Goulet MT, Hagmann WK, Lin LS, Lanza TJ Jr, Jewell JP, Liu P, Shah SK, Qi H, Tong X, Wang J, Xu SS, Francis B, Strack AM, MacIntyre DE, Shearman LP.

J Pharmacol Exp Ther. 2007 Jun;321(3):1013-22. Epub 2007 Feb 27.

7.

Synthesis and SAR of heterocyclic carboxylic acid isosteres based on 2-biarylethylimidazole as bombesin receptor subtype-3 (BRS-3) agonists for the treatment of obesity.

Hadden M, Goodman A, Guo C, Guzzo PR, Henderson AJ, Pattamana K, Ruenz M, Sargent BJ, Swenson B, Yet L, Liu J, He S, Sebhat IK, Lin LS, Tamvakopoulos C, Peng Q, Kan Y, Palyha O, Kelly TM, Guan XM, Metzger JM, Reitman ML, Nargund RP.

Bioorg Med Chem Lett. 2010 May 1;20(9):2912-5. doi: 10.1016/j.bmcl.2010.03.028. Epub 2010 Mar 12.

PMID:
20347296
8.

Ability of various bombesin receptor agonists and antagonists to alter intracellular signaling of the human orphan receptor BRS-3.

Ryan RR, Weber HC, Hou W, Sainz E, Mantey SA, Battey JF, Coy DH, Jensen RT.

J Biol Chem. 1998 May 29;273(22):13613-24.

9.

Appetite-modifying effects of bombesin receptor subtype-3 agonists.

Majumdar ID, Weber HC.

Handb Exp Pharmacol. 2012;(209):405-32. doi: 10.1007/978-3-642-24716-3_19. Review.

PMID:
22249826
10.

Synergistic interaction between neuropeptide Y1 and Y5 receptor pathways in regulation of energy homeostasis.

Mashiko S, Moriya R, Ishihara A, Gomori A, Matsushita H, Egashira S, Iwaasa H, Takahashi T, Haga Y, Fukami T, Kanatani A.

Eur J Pharmacol. 2009 Aug 1;615(1-3):113-7. doi: 10.1016/j.ejphar.2009.05.018. Epub 2009 May 29.

PMID:
19482021
11.

Rational design of a peptide agonist that interacts selectively with the orphan receptor, bombesin receptor subtype 3.

Mantey SA, Coy DH, Pradhan TK, Igarashi H, Rizo IM, Shen L, Hou W, Hocart SJ, Jensen RT.

J Biol Chem. 2001 Mar 23;276(12):9219-29. Epub 2000 Dec 8.

12.

Regulation of body temperature and brown adipose tissue thermogenesis by bombesin receptor subtype-3.

Lateef DM, Abreu-Vieira G, Xiao C, Reitman ML.

Am J Physiol Endocrinol Metab. 2014 Mar;306(6):E681-7. doi: 10.1152/ajpendo.00615.2013. Epub 2014 Jan 22.

13.

Mice lacking bombesin receptor subtype-3 develop metabolic defects and obesity.

Ohki-Hamazaki H, Watase K, Yamamoto K, Ogura H, Yamano M, Yamada K, Maeno H, Imaki J, Kikuyama S, Wada E, Wada K.

Nature. 1997 Nov 13;390(6656):165-9.

PMID:
9367152
14.

Antiobesity-like effects of the 5-HT2C receptor agonist WAY-161503.

Rosenzweig-Lipson S, Zhang J, Mazandarani H, Harrison BL, Sabb A, Sabalski J, Stack G, Welmaker G, Barrett JE, Dunlop J.

Brain Res. 2006 Feb 16;1073-1074:240-51. Epub 2006 Jan 20.

PMID:
16430874
15.

In vitro and in vivo pharmacology of CP-945,598, a potent and selective cannabinoid CB(1) receptor antagonist for the management of obesity.

Hadcock JR, Griffith DA, Iredale PA, Carpino PA, Dow RL, Black SC, O'Connor R, Gautreau D, Lizano JS, Ward K, Hargrove DM, Kelly-Sullivan D, Scott DO.

Biochem Biophys Res Commun. 2010 Apr 2;394(2):366-71. doi: 10.1016/j.bbrc.2010.03.015. Epub 2010 Mar 6.

PMID:
20211605
16.

Small-molecule melanin-concentrating hormone-1 receptor antagonists require brain penetration for inhibition of food intake and reduction in body weight.

Eric Hu X, Wos JA, Dowty ME, Suchanek PM, Ji W, Chambers JB, Benoit SC, Clegg DJ, Reizes O.

J Pharmacol Exp Ther. 2008 Jan;324(1):206-13. Epub 2007 Oct 11.

17.

Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents.

Shearman LP, Stribling DS, Camacho RE, Rosko KM, Wang J, Tong S, Feng Y, Marsh DJ, Yu H, Guan X, Spann SK, Macneil DJ, Fong TM, Metzger JM, Goulet MT, Hagmann WK, Plummer CW, Finke PE, Mills SG, Shah SK, Truong Q, Van der Ploeg LH, Macintyre DE, Strack AM.

Eur J Pharmacol. 2008 Jan 28;579(1-3):215-24. Epub 2007 Oct 25.

PMID:
18021763
18.

Bombesin receptor subtype 3 as a potential target for obesity and diabetes.

González N, Moreno P, Jensen RT.

Expert Opin Ther Targets. 2015;19(9):1153-70. doi: 10.1517/14728222.2015.1056154. Epub 2015 Jun 12. Review.

PMID:
26066663
19.

Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y(1) receptor antagonist.

Antal-Zimanyi I, Bruce MA, Leboulluec KL, Iben LG, Mattson GK, McGovern RT, Hogan JB, Leahy CL, Flowers SC, Stanley JA, Ortiz AA, Poindexter GS.

Eur J Pharmacol. 2008 Aug 20;590(1-3):224-32. doi: 10.1016/j.ejphar.2008.06.032. Epub 2008 Jun 12.

PMID:
18573246
20.

Effects of a selective melanin-concentrating hormone 1 receptor antagonist on food intake and energy homeostasis in diet-induced obese mice.

Kowalski TJ, Spar BD, Weig B, Farley C, Cook J, Ghibaudi L, Fried S, O'Neill K, Del Vecchio RA, McBriar M, Guzik H, Clader J, Hawes BE, Hwa J.

Eur J Pharmacol. 2006 Mar 27;535(1-3):182-91. Epub 2006 Mar 13.

PMID:
16540104
Items per page

Supplemental Content

Write to the Help Desk